Chonluten
Research OnlyA synthetic tripeptide (Glu-Asp-Gly) developed by Vladimir Khavinson for gastrointestinal tissue support. Shares the same amino acid sequence as Kristagen but is marketed for digestive system rather than immune function. Limited to Russian studies with no Western validation or clinical trials.
EDG-GI · Glu-Asp-Gly (GI) · GI tract tripeptide · Intestinal peptide
Mostly preclinical · 1 human study
- Preclinical
- 75%
- Human research
- 13%
Based on 8 cited sources
Numeric assessment unreviewed
A historical numeric score is recorded but has not passed a current, compound-specific assessment review. No numeric score is displayed.
This is a limitation of the numeric assessment, not a measured absence of benefit. It does not re-review the separately recorded catalogue classification or establish efficacy or safety.
The proposed mechanisms of Chonluten are based entirely on Russian bioregulator research with no independent Western validation. Human mechanistic data from controlled trials is completely absent.
How It Works (Simplified)
Chonluten is claimed to target gastrointestinal tissue through peptide bioregulation:
Proposed to interact with DNA in GI epithelial cells, modulating expression of genes involved in tissue maintenance and repair.
Claimed to enhance mucin production in gastric epithelium, potentially supporting the protective mucus barrier of the stomach and intestines.
Proposed to maintain intestinal epithelial barrier function through normalization of cell turnover and tight junction proteins.
Within bioregulator theory, claimed to restore youthful gene expression patterns in aging digestive tissue. Completely unvalidated.
Critical Note: These pathways are entirely theoretical, based on the general bioregulator framework proposed by Khavinson. No specific molecular targets or validated mechanisms have been identified for Chonluten.
Important Limitations
- 100% of research from Russian institutes with no independent validation
- Same sequence as Kristagen (immune peptide) - raises questions about tissue specificity claims
- No controlled human clinical trials exist
- No indexed peer-reviewed publications in Western journals
- Mechanism of tissue-specific targeting is unexplained
- No pharmacokinetic data on absorption, distribution, or bioavailability
- Quality and methodology of Russian studies cannot be independently verified
- The concept of identical peptides having different tissue effects lacks scientific basis
Comparison with Better-Studied Alternatives
| Aspect | Chonluten | BPC-157 |
|---|---|---|
| Research Base | Russian only | International |
| Published Studies | ~5-10 | 100+ |
| Mechanism Clarity | Vague/theoretical | Specific pathways identified |
| Independent Validation | None | Multiple groups |
| Human Data | Anecdotal only | Limited but exists |
Based on bioregulator theory: Initial peptide-DNA interactions may begin in GI epithelial cells. No objective markers have been established to confirm early effects.
Continued treatment as per Russian protocols. Claimed gene expression modulation in digestive tissue. Subjective improvements in digestive comfort reported in uncontrolled observations.
Extended use as per bioregulator cycling protocols. Tissue-level changes proposed but not validated by objective measures. Russian protocols suggest 10-20 day treatment cycles.
Long-term protocols involve cyclical use with rest periods. Maintenance of proposed benefits requires ongoing treatment. No long-term safety or efficacy data available.
Research-based observations
This timeline reflects observations from published clinical and preclinical studies. Individual responses may vary significantly. This is not a guarantee of effects or a dosing schedule. Consult qualified healthcare providers for personalized guidance.
BPC-157
CompatibleBoth target gastrointestinal tissue - BPC-157 for acute healing and repair, Chonluten for proposed tissue regulation. No known direct interactions.
Epithalon
CompatibleBoth Khavinson bioregulator peptides with distinct tissue targets - epithalon for pineal/longevity, Chonluten for GI tract. No contraindications reported.
Thymalin
CompatibleBoth Russian bioregulators - Thymalin for immune function, Chonluten for digestive system. May be used in combination protocols.
Kristagen
CompatibleIdentical amino acid sequence (EDG) but marketed for different tissue targets - Kristagen for immune system, Chonluten for gastrointestinal tract.
Laennec
CompatibleDifferent regenerative approaches - Laennec is placental extract for tissue repair, Chonluten is synthetic peptide for GI regulation.
Research Note: Interaction data is based on published literature, mechanistic understanding, and theoretical considerations. Most peptide combinations lack direct clinical study. This information is for educational purposes only and does not constitute medical advice. Always consult qualified healthcare providers.
Key Studies Cited
Use the source links in the research discussion above to inspect the referenced records.
This dossier synthesizes available evidence from peer-reviewed literature, regulatory documents, and clinical trial registries. Evidence strength labels summarize the cited material for this entry and should be read alongside its population, model, and study limitations.
For complete methodology details, see our Methodology page.
Important Disclaimer
This dossier is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.
Get Research Alerts
New dossiers and major study summaries delivered to your inbox. Evidence-graded, citation-backed research you can trust.
No spam. Unsubscribe anytime.
Compare Chonluten
Related Peptides
225Ac-DOTA-LM3
Actinium-225-DOTA-LM3 · 225Ac-DOTA-JR11 · Alpha-PRRT +1
An alpha-emitting radiolabeled somatostatin receptor antagonist for peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors. Unlike conventional beta-emitting Lu-177 therapies and SSTR agonists, 225Ac-DOTA-LM3 combines the higher cell-killing power of alpha particles with antagonist binding for enhanced tumor targeting. Clinical stage investigational therapy showing promise in Lu-177-refractory patients.
Bronchogen
AEDL · Ala-Glu-Asp-Leu · Bronchial tetrapeptide +1
A synthetic tetrapeptide (Ala-Glu-Asp-Leu) developed by Russian scientist Vladimir Khavinson for bronchial and respiratory tissue support. Claimed to modulate bronchial epithelium gene expression and provide respiratory protective effects. No Western clinical validation; all evidence from Russian bioregulator research.
BT5528
Bicycle Toxin Conjugate 5528 · EphA2-BTC
A first-in-class Bicycle Toxin Conjugate (BTC) targeting EphA2-expressing tumors, developed by Bicycle Therapeutics. Combines a constrained bicyclic peptide targeting moiety with the cytotoxic payload MMAE. The first-in-human Phase I (45 patients, advanced solid tumors) reported a 6.7% overall response rate and 20% disease control at the recommended Phase 2 dose; expansion ongoing.
Cardiogen
AED · Ala-Glu-Asp · Cardiac tripeptide
A synthetic tripeptide (Ala-Glu-Asp, AED) developed by Russian scientist Vladimir Khavinson and marketed as a cardiac "bioregulator." Despite that marketing, no PubMed-indexed study has examined AED in heart, cardiomyocyte, or myocardial tissue. The only published AED research is in vitro and non-cardiac — anti-aging gene-expression effects in cultured stem cells, fibroblasts, kidney and immune cells. No human or animal data and no regulatory approval anywhere.
Chelohart
Heart cytamin · Cardiac peptide supplement · A-14 heart peptides
A cytamin-class peptide supplement derived from cardiac (heart) tissue, part of the Khavinson bioregulator framework. Marketed as an oral supplement for cardiac health support. Contains peptide complexes rather than defined sequences. Very limited clinical validation, primarily Russian-language literature.
EVX-01
EVX01 · Evaxion EVX-01
EVX-01 is an investigational, patient-specific neoantigen peptide vaccine studied with anti-PD-1 therapy in advanced melanoma. Two small single-arm cohorts show vaccine-specific T-cell responses and observed tumor responses, but they cannot establish how much EVX-01 adds to checkpoint treatment.
Compared With
4 comparisonsConditions Studied
3 entries- Chonluten for Digestive Health Chonluten is marketed for general digestive system support based on the Khavinson bioregulator theory that tissue-specific peptide…
- Chonluten for Gastrointestinal Protection Russian research claims Chonluten supports gastric and intestinal mucosa integrity. Animal studies suggest improvements in tissue…
- Chonluten for Age-Related GI Decline Within the bioregulator framework, Chonluten is positioned to address age-related digestive system changes. Khavinson's theory sug…